[go: up one dir, main page]

Trentini et al., 2019 - Google Patents

Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1

Trentini et al., 2019

View PDF
Document ID
2338542507167701620
Author
Trentini A
Bellini T
Bonaccorsi G
Cavicchio C
Hanau S
Passaro A
Cervellati C
Publication year
Publication venue
Journal of Clinical Biochemistry and Nutrition

External Links

Snippet

Materials and Methods Subjects. The present study consisted in the re-examination of data collected from three different cohorts: 1) subjects attending the metabolic outpatient clinic of Sant'Anna University Hospital (Ferrara, Italy); 2) outpatients undergoing bone densitometry …
Continue reading at www.jstage.jst.go.jp (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Similar Documents

Publication Publication Date Title
Florath et al. Type 2 diabetes and leucocyte DNA methylation: an epigenome-wide association study in over 1,500 older adults
Squitti et al. Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators
Kjær et al. Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoGuo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study
Li et al. Significance of lipoprotein (a) levels in familial hypercholesterolemia and coronary artery disease
Cantonwine et al. Urinary concentrations of bisphenol A and phthalate metabolites measured during pregnancy and risk of preeclampsia
Zeljkovic et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality
Wang et al. Association of serum levels of perfluoroalkyl substances with gestational diabetes mellitus and postpartum blood glucose
Trentini et al. Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1
Pihlajamäki et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia
US20150051161A1 (en) Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
Min et al. Serum levels of leptin, osteopontin, and sclerostin in patients with and without knee osteoarthritis
Blagojević et al. Evaluation of a summary score for dyslipidemia, oxidative stress and inflammation (the DOI score) in women with polycystic ovary syndrome and its relationship with obesity
Holven et al. Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
Porkka et al. Phenotype expression in familial combined hyperlipidemia
Eny et al. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence
Guzzardi et al. Exposure to persistent organic pollutants predicts telomere length in older age: results from the Helsinki birth cohort study
Chielle et al. Evaluation of salivary oxidative parameters in overweight and obese young adults
Medeiros et al. Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia
Wang et al. The relationship of bone mineral density to oxidant/antioxidant status and inflammatory and bone turnover markers in a multicenter cross-sectional study of young men with ankylosing spondylitis
Murr et al. Cross-sectional association of salivary proteins with age, sex, body mass index, smoking, and education
Zare-Mirzaie et al. The correlation between serum vitamin D level and Total antioxidant capacity in diabetic and non-diabetic subjects in Iran
Polat et al. The relationship between frailty and serum alpha klotho levels in geriatric patients
Abaj et al. Caveolin-1 genetic polymorphism interacts with PUFA to modulate metabolic syndrome risk
Carmena et al. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia: clinical and laboratory observations
RU2462718C1 (en) Method for evaluating clinical effectiveness in lipidemia